ArticleDrug delivery2021
Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug-eluting beads transarterial chemoembolization vs conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma in adult patients: a systematic review and update meta-analysis of observational studies.Frontiers in oncology · 2024Pooled it
- Efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization for unresectable gastrointestinal stromal tumor liver metastases after failure of targeted therapy: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Microalgae-based biodegradable embolic agent for the treatment of hepatocellular carcinoma through transarterial embolization.Journal of nanobiotechnology · 2025Article
- Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching.World journal of surgical oncology · 2025Article
- Refining Intra-Arterial Therapy Selection for Large Hepatocellular Carcinoma: A Deep Learning Approach Based on Covariate Interaction Analysis.Journal of hepatocellular carcinoma · 2025Article
- Combination of drug-eluting bead transarterial chemoembolization and PD-1 inhibitor for treatment of unresectable head and neck squamous cell carcinoma: an initial, short-term clinical experience in a single-center retrospective cohort study.Frontiers in immunology · 2025Article
- 5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis.Scientific reports · 2024Article
- The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.Irish journal of medical science · 2024Article
- Celecoxib and cisplatin dual-loaded microspheres synergistically enhance transarterial chemoembolization effect of hepatocellular carcinoma.Materials today. Bio · 2024Article
- Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study.Frontiers in oncology · 2023Article
- Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer.Canadian journal of gastroenterology & hepatology · 2023Article
- [Analysis of curative effects of chemoembolization with drug-loaded microspheres of different particle sizes for the treatment of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer.Frontiers in surgery · 2022Article
- CalliSpheresFrontiers in oncology · 2022Article
- Early changes in peripheral blood cytokine levels after the treatment of metastatic hepatic carcinoma with CalliSpheres microspheres drug-eluting beads transcatheter arterial chemoembolization.Frontiers in oncology · 2022Article
- Simultaneous CSM-TACE with CalliSpheresFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to compare efficacy and safety of HepaSpheres and CalliSpheres in unresectable large hepatocellular carcinoma (HCC) patients. One hundred and twenty-seven unresectable large HCC patients receiving drug-eluting bead transarterial chemoembolization (DEB-TACE) treatment with CalliSpheres or HepaSpheres microspheres were analyzed. Treatment response, Karnofsky performance status (KPS) score, adverse events, main liver function indexes, time to progression (TTP), and overall survival (OS) were analyzed. Objective response rate (82.7% vs. 63.8%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.